Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Fulcrum Therapeutics drug program...
Business drug discontinuation

Fulcrum Therapeutics drug program discontinued

Analysis based on 16 articles · First reported Jul 15, 2026 · Last updated Jul 27, 2026

Sentiment
-40
Attention
2
Articles
16
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Fulcrum Therapeutics' stock dropped 51% on the news, erasing significant market value. The investigation by Kaplan Fox may lead to further legal costs and reputational damage.

Biotechnology Pharmaceuticals
Event Summary

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced on June 1, 2026, the discontinuation of its pociredir program for sickle cell disease after the FDA concluded that targeting the PRC2 complex carries malignancy risk. The stock fell 51% the next day. Kaplan Fox & Kilsheimer LLP is investigating potential securities violations.

Key Actions
100 Fulcrum Therapeutics discontinued drug program
90 United States — Food and Drug Administration concluded malignancy risk Fulcrum Therapeutics
30 Kaplan Fox & Kilsheimer investigating securities violations Fulcrum Therapeutics
Entities Involved
stock
Fulcrum Therapeutics
Fulcrum Therapeutics discontinued its pociredir program, causing a 51% stock decline and triggering a securities investigation.
Importance 100.0 Sentiment -80.0
govactor
United States — Food and Drug Administration
The FDA concluded that PRC2 inhibitors carry malignancy risk, leading to the discontinuation of Fulcrum's pociredir program.
Importance 50.0 Sentiment 0.0
priv
Kaplan Fox & Kilsheimer
Kaplan Fox is investigating potential securities violations against Fulcrum Therapeutics, representing investors who suffered losses.
Importance 30.0 Sentiment 0.0
exch
Nasdaq
Fulcrum Therapeutics is listed on Nasdaq under ticker FULC, which experienced a significant price decline.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Kaplan Fox & Kilsheimer
United States — Food and Drug Administration related ↔ Nasdaq
Kaplan Fox & Kilsheimer related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.